When you can get a blood test for a rare condition: the UK’s most expensive test

The cost of blood tests for blood cancers, including leukemia, lymphoma, and other rare diseases has reached £300,000 per patient.

The total cost for blood tests to treat a patient with an abnormal blood sample is likely to reach around £300 million, according to research by the British Society for Clinical Oncology.

Blood tests for the most common blood cancers are typically carried out by an oncologist who then has the blood drawn from the patient.

In rare cases, however, doctors have used a biopsy technique to extract cells from the body to test for particular cancer cells.

There are many different ways to perform a biopsied sample, with the most expensive being to take the sample from the abdomen.

But Dr Ian Dickson from the University of Manchester and colleagues, from Queen Mary University of London and the University College London, said that the most commonly performed biopsy was the blood from the groin.

The researchers tested all 50 UK patients in order to compare the quality of their results with those of patients in other parts of the world.

Dr Dickson said the average time for the patient’s blood sample to be extracted from the chest was 2.8 hours and for the groin, 3.5 hours.

The study compared the results of all 50 patients with those in other countries.

Dr Richard Walker from the Royal College of Surgeons of Great Britain said that while the cost of testing was “huge”, it was “not cheap” and that some patients did not have a suitable test.

“The main thing is that if you have cancer, there is a test,” he said.

“And if you don’t have a test, the cancer can get to you.”

The Royal College’s Dr Walker said that in the UK, there were around 200,000 people who were diagnosed with cancer in the last decade, with almost all diagnosed in the past 15 years.

“In the UK we do not see many people with cancer because of the number of tests that are required to get an accurate diagnosis,” he told BBC News.

Dr Walker added that it was not a problem with the quality or availability of tests.

“I would be a little bit surprised if there were a huge number of cancer patients in the country, but we don’t know,” he added.

In addition to the cost, there are other health issues that need to be addressed before the tests are used, including possible side effects such as fever, swelling and diarrhoea.

Dr Elliott said that testing could be considered an alternative to chemotherapy.

“It may be an alternative, but if the side effects of chemotherapy are outweighed by the benefits of the testing, it is not worth the money,” she said.